Form 8-K - Current report:
SEC Accession No. 0001213900-25-001156
Filing Date
2025-01-06
Accepted
2025-01-06 16:01:28
Documents
16
Period of Report
2025-01-06
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0226772-8k_cerotherap.htm   iXBRL 8-K 39125
2 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCOR ea022677201ex3-1_cero.htm EX-3.1 9738
3 PRESS RELEASE, DATED JANUARY 6, 2025 ea022677201ex99-1_cero.htm EX-99.1 13777
  Complete submission text file 0001213900-25-001156.txt   296403

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cero-20250106.xsd EX-101.SCH 3798
5 XBRL DEFINITION FILE cero-20250106_def.xml EX-101.DEF 26673
6 XBRL LABEL FILE cero-20250106_lab.xml EX-101.LAB 36817
7 XBRL PRESENTATION FILE cero-20250106_pre.xml EX-101.PRE 25297
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0226772-8k_cerotherap_htm.xml XML 6059
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

IRS No.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 25510974
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)